INCA-GYN001: Erlotinib added to cisplatin and definitive radiotherapy in untreated patients with locally advanced squamous cell cervical carcinoma—Final report of a phase II trial.

Rodrigues, A. N.; Small, I. A.; Carmo, Claudio Calazan do; Moralez, G. M.; Erlich, F.; Grazziotin, Rachele; Lewer, M. H.; Camisão, C.; Alves, Flávia Vieira Guerra; Ferreira, Cintia Giselle Martins

doi:10.1200/jco.2011.29.15_suppl.5033

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Erlotinib has been studied in 2 previous phase II studies in women with cervical cancer [12, 13]. The first study was an open-label single-arm trial that enrolled 25 patients with recurrent or metastatic disease who had all previously received chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…This report describes the case of a woman with recurrent metastatic cervical cancer who developed a sustained complete response following treatment with radiation therapy and adjuvant chemotherapy with cisplatin and topotecan, followed by maintenance therapy with a combination of topotecan and the EGFR inhibitor erlotinib. Erlotinib has been studied in 2 previous phase II studies in women with cervical cancer [ 12 , 13 ]. The first study was an open-label single-arm trial that enrolled 25 patients with recurrent or metastatic disease who had all previously received chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…A second study evaluated erlotinib in combination with cisplatin in 36 patients undergoing definitive radiation therapy for locally advanced disease. Thirty-four patients (94%) had a complete response, and 2 patients (6%) had a partial response [ 13 ]. In both studies, erlotinib was well tolerated, and the most common side effects were skin rash, fatigue, and gastrointestinal toxic effects.…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported that human papillomavirus 16, the primary causative agent of cervical cancer, stimulates EGFR expression on epithelial cells [ 11 ]. On the basis of these data, erlotinib has been evaluated in the treatment of cervical carcinoma [ 12 , 13 ]. In this report, we describe a case of sustained complete response in a patient with distant recurrent cervical cancer treated successfully with local radiation therapy followed by adjuvant chemotherapy and erlotinib-based maintenance therapy.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases

Callegaro-Filho

Kavanagh

Nick³

et al. 2014

Case Rep Oncol

View full text Add to dashboard Cite

Introduction: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease. Epidermal growth factor receptor (EGFR) inhibitors may have a role in this setting. Case Description: A 53-year-old woman with stage IB2 squamous cell carcinoma of the cervix was initially treated with chemoradiation. Six months after completing treatment, she developed a recurrence in the common iliac and para-aortic lymph nodes above the previous radiation field and was treated with additional radiation therapy. Two years later, she developed recurrent disease in the left supraclavicular lymph nodes and was treated with chemoradiation followed by 3 cycles of adjuvant cisplatin and topotecan. She had a complete response and was placed on maintenance therapy with topotecan and erlotinib, which was well tolerated and produced minimal side effects. After 20 months of maintenance therapy, it was discontinued given the long interval without evidence of disease. The patient is currently without evidence of disease 5 years after completing the topotecan-erlotinib treatment. Conclusion: We noted a sustained response in a patient with recurrent metastatic cervical cancer treated with radiotherapy, cisplatin, and topotecan followed by maintenance therapy with topotecan and erlotinib. Further evaluation of the role of EGFR inhibitors in this setting should be considered given their favorable toxicity profile and biological relevance.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases

Callegaro-Filho

Kavanagh

Nick³

et al. 2014

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

“…Une équipe brésilienne a choisi l'erlotinib, inhibiteur de tyrosine-kinase [20]. Quarante et une patientes étaient incluses avec des tumeurs de stades IIb à IIIB.…”

Section: Dossierunclassified

Gynaecological cancers

Petit¹

2011

Oncologie

View full text Add to dashboard Cite

INCA-GYN001: Erlotinib added to cisplatin and definitive radiotherapy in untreated patients with locally advanced squamous cell cervical carcinoma—Final report of a phase II trial.

Cited by 2 publications

References 0 publications

Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases

Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases

Gynaecological cancers

Contact Info

Product

Resources

About